- Home
- PAAS vs JAZZ Comparison
PAAS vs JAZZ Comparison
Compare PAAS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAAS
- JAZZ
- Stock Information
- Founded
- PAAS 1994
- JAZZ 2003
- Country
- PAAS Canada
- JAZZ Ireland
- Employees
- PAAS N/A
- JAZZ N/A
- Industry
- PAAS
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- PAAS
- JAZZ Health Care
- Exchange
- PAAS Nasdaq
- JAZZ Nasdaq
- Market Cap
- PAAS 7.8B
- JAZZ 6.5B
- IPO Year
- PAAS 1995
- JAZZ 2007
- Fundamental
- Price
- PAAS $20.58
- JAZZ $122.97
- Analyst Decision
- PAAS Buy
- JAZZ Buy
- Analyst Count
- PAAS 5
- JAZZ 14
- Target Price
- PAAS $24.00
- JAZZ $173.93
- AVG Volume (30 Days)
- PAAS 3.3M
- JAZZ 646.0K
- Earning Date
- PAAS 11-05-2024
- JAZZ 11-06-2024
- Dividend Yield
- PAAS 1.94%
- JAZZ N/A
- EPS Growth
- PAAS N/A
- JAZZ 458.10
- EPS
- PAAS N/A
- JAZZ 7.04
- Revenue
- PAAS $2,673,400,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- PAAS $23.92
- JAZZ $7.51
- Revenue Next Year
- PAAS $12.06
- JAZZ $6.82
- P/E Ratio
- PAAS N/A
- JAZZ $17.48
- Revenue Growth
- PAAS 32.22
- JAZZ 5.23
- 52 Week Low
- PAAS $12.16
- JAZZ $99.06
- 52 Week High
- PAAS $26.05
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- PAAS 38.14
- JAZZ 54.14
- Support Level
- PAAS $20.28
- JAZZ $119.14
- Resistance Level
- PAAS $24.24
- JAZZ $125.77
- Average True Range (ATR)
- PAAS 0.77
- JAZZ 3.19
- MACD
- PAAS -0.24
- JAZZ -0.27
- Stochastic Oscillator
- PAAS 7.41
- JAZZ 55.59
About PAAS Pan American Silver Corp.
Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.